NRx Pharmaceuticals Investor Relations Material

NRx Pharmaceuticals Inc. (NRXP) is a clinical-stage pharmaceutical company focused on developing novel therapeutics for the treatment of central nervous system disorders. The company's portfolio includes ZYESAMI, an investigational drug for COVID-19 related respiratory failure, and oral therapeutics NRX-100 and NRX-101 for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company is headquartered in Wilmington, Delaware, and its shares are listed on the Nasdaq.